We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+33.14%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.1B
AUM Growth
+$1.15B
(+19%)
Cap. Flow
-$127M
Cap. Flow
% of AUM
-1.79%
Top 10 Holdings %
Top 10 Hldgs %
31.14%
Holding
166
New
24
Increased
29
Reduced
28
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BNR
Burning Rock Biotech
BNR
|
+$130M |
| 2 |
RPTX
Repare Therapeutics
RPTX
|
+$110M |
| 3 |
Oric Pharmaceuticals
ORIC
|
+$93.3M |
| 4 |
Biogen
BIIB
|
+$70.8M |
| 5 |
Theravance Biopharma
TBPH
|
+$60.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$237M |
| 2 |
Pfizer
PFE
|
+$98.3M |
| 3 |
Gilead Sciences
GILD
|
+$98M |
| 4 |
Alector
ALEC
|
+$64.9M |
| 5 |
HCA Healthcare
HCA
|
+$63.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.21% |
| 2 | Financials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $311M | 4.38% |
7,406,307
| – | – |
|
|
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
| $264M | 3.72% |
9,614,280
| – | – |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
| $242M | 3.41% |
2,156,000
+84,615
| +4% | +$8.98M |
|
|
4
Ascendis Pharma A/S
ASND
$16.7B
| $231M | 3.25% |
1,562,986
-1,724,414
| -52% | -$237M |
|
|
PRVL
5
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $206M | 2.9% |
13,822,463
| – | – |
|
6
Merck
MRK
$326B
| $200M | 2.82% |
2,713,377
| – | – |
|
7
Vertex Pharmaceuticals
VRTX
$124B
| $193M | 2.72% |
666,100
-71,300
| -10% | -$19.3M |
|
|
8
Biogen
BIIB
$30.4B
| $192M | 2.7% |
715,900
+235,500
| +49% | +$70.8M |
|
9
Passage Bio
PASG
$14.7M
| $190M | 2.68% |
348,145
| – | – |
|
10
Iovance Biotherapeutics
IOVA
$2.1B
| $182M | 2.57% |
6,645,100
+1,096,774
| +20% | +$36.1M |
|
|
TPTX
11
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $177M | 2.5% |
2,745,327
| – | – |
|
12
Boston Scientific
BSX
$68.5B
| $170M | 2.4% |
4,847,300
| – | – |
|
13
Bristol-Myers Squibb
BMY
$130B
| $169M | 2.39% |
2,882,200
+407,400
| +16% | +$24.4M |
|
14
Natera
NTRA
$36.1B
| $162M | 2.27% |
3,240,514
-106,486
| -3% | -$4.27M |
|
|
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $159M | 2.24% |
2,867,910
+526,210
| +22% | +$22.5M |
|
|
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $151M | 2.13% |
1,324,100
-99,200
| -7% | -$9.62M |
|
|
17
Alector
ALEC
$169M
| $146M | 2.06% |
5,975,322
-2,352,369
| -28% | -$64.9M |
|
18
Neurocrine Biosciences
NBIX
$18.4B
| $145M | 2.04% |
1,185,915
+30,900
| +3% | +$3.41M |
|
19
Arcutis Biotherapeutics
ARQT
$3.55B
| $141M | 1.99% |
4,673,850
| – | – |
|
|
BNR
20
Burning Rock Biotech
BNR
$96.9M
| $128M | 1.8% |
+474,607
| New | +$130M |
|
21
Humana
HUM
$46.7B
| $109M | 1.53% |
280,300
| – | – |
|
|
RPTX
22
DELISTED
Repare Therapeutics
RPTX
| $106M | 1.5% |
+3,426,325
| New | +$110M |
|
|
23
Oric Pharmaceuticals
ORIC
$1.23B
| $98.6M | 1.39% |
+2,921,967
| New | +$93.3M |
|
24
Agios Pharmaceuticals
AGIO
$2.14B
| $92.4M | 1.3% |
1,728,421
+75,725
| +5% | +$3.51M |
|
25
DexCom
DXCM
$28.9B
| $91.8M | 1.29% |
905,600
-446,400
| -33% | -$39.9M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q2 2020 Portfolio in Review
As of Q2 2020, OrbiMed held 166 positions worth $7.1B, up 19% from $5.95B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
OrbiMed's Q2 2020 filing shows 24 new, 29 increased, 28 reduced and 31 closed positions. Its largest new stake was Burning Rock Biotech: 474,607 shares worth $128M. The largest sale was Ascendis Pharma A/S, an estimated $237M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Financials.
- OrbiMed's largest Q2 2020 buy was Burning Rock Biotech: 474,607 shares worth $128M.
- OrbiMed added most to Biogen in Q2 2020, an estimated $70.8M increase.
- OrbiMed's biggest Q2 2020 reduction was Ascendis Pharma A/S, cutting an estimated $237M.
- OrbiMed fully exited Pfizer in Q2 2020, selling an estimated $98.3M.
- OrbiMed's ten largest holdings make up 31% of its $7.1B portfolio in Q2 2020.
- OrbiMed opened 24 new positions and closed 31 in Q2 2020.
- OrbiMed's portfolio value rose 19% quarter-over-quarter to $7.1B.
Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.